THIS QUARTER · Q4 2026
Readouts companies said would come this quarter
Q4 2026 (Oct 1, 2026 – Dec 31, 2026). Each row quotes a company's latest sentence about a readout, as written, with the SEC filing it came from. 15 programs as of .
Add to Google Calendar Apple Calendar One all-day entry per program on the last day of the period the company stated. No sign-up; ORION stores nothing about subscribers.
How this list is made
- Each program page on this site quotes the company's latest sentence about its readout, from an SEC filing, as written.
- A program is listed when a calendar period stated in that sentence ends inside this quarter: a quarter (“Q4 2026”), a half (“second half of 2026”), a month, “late 2026” or a year (“in 2026”). Wording such as “early” or “mid” has no stated end and is not read. The period that put a row here is in bold.
- A period stated for enrollment or a commercial launch is not read.
- Status: Company’s stated window: still open — the stated period has not ended. results filed — the founder-reviewed record holds the results filing, linked. A program whose stated period has ended with no results filing held is not listed.
- A sentence that names a month is counted to that month's last day. If the period read here is not that month, no count is shown; the company's wording stands as written.
- Each row carries its review label: Checked by founder — compared by hand with the SEC original by ORION's founder; Quote matched to filing (not yet reviewed by founder) — the sentence was matched to the SEC original by machine, not compared by hand.
- No forecast. The list repeats what companies wrote.
| Company (ticker) | Program | Company wording, as written | Date | SEC original | Status |
|---|---|---|---|---|---|
| Rapport Therapeutics (RAPP) | RAP-219 / bipolar mania Phase 2 · Topline results Checked by founder | “topline results are expected in October 2026” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 12 | |
| Biohaven (BHVN) | opakalim / RISE3 focal epilepsy · Topline results Checked by founder | “Dosing continues in BHV7000-303 and topline data remain on track for the second half of 2026.” | SEC Form 8-K | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Scholar Rock (SRRK) | SRK-439 · topline data Checked by founder | “A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | sabirnetug Quote matched to filing (not yet reviewed by founder) | “ALTITUDE-AD topline results expected in late 2026, inclusive of efficacy, safety and biomarker data” | SEC Form 8-K | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Structure Therapeutics Inc. (GPCR) | aleniglipron Quote matched to filing (not yet reviewed by founder) | “Additional clinical data expected in the fourth quarter of 2026 could further define aleniglipron’s differentiated clinical profile in terms of the quality of weight loss, treatment of patients with T2DM and the transition from approved injectable incretin medicines. Expected data readouts include: · Phase 2 Body Composition clinical trial (NCT07169942): Results from a 44-week study evaluating aleniglipron’s effects on body fat and overall body composition. · Phase 2 T2DM clinical trial (NCT07400588): Results in adults living with T2DM and obesity or overweight. · Phase 1 SWITCH clinical trial: Results evaluating the transition from approved injectable GLP-1 medicine to once-daily oral aleniglipron.” | SEC Form 8-K | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Zura Bio Ltd (ZURA) | tibulizumab Quote matched to filing (not yet reviewed by founder) | “Topline data expected from HS and SSc Phase 2 studies in Q4 2026 and H1 2027, respectively” | SEC Form 8-K | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Karyopharm Therapeutics Inc. (KPTI) | selinexor Quote matched to filing (not yet reviewed by founder) | “We expect to report topline data from this event-driven trial in the second half of 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Annexon, Inc. (ANNX) | vonaprument Quote matched to filing (not yet reviewed by founder) | “The Month 15 primary endpoint remains on track for the fourth quarter of 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| BioAge Labs, Inc. (BIOA) | BGE-102 Quote matched to filing (not yet reviewed by founder) | “We anticipate reporting topline data from QUELL-CV in the second half of 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Geron Corporation (GERN) | imetelstat Quote matched to filing (not yet reviewed by founder) | “Based on our current planning assumptions for event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Entrada Therapeutics, Inc. (TRDA) | VX-670 Quote matched to filing (not yet reviewed by founder) | “Vertex is on track to complete dosing and report results in the second half of 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Moderna, Inc. (MRNA) | Intismeran autogene Quote matched to filing (not yet reviewed by founder) | “We expect Phase 3 adjuvant melanoma data potentially in 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Moderna, Inc. (MRNA) | mRNA-3927 Quote matched to filing (not yet reviewed by founder) | “We expect potential data in 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Alnylam Pharmaceuticals, Inc. (ALNY) | ALN-6400 Quote matched to filing (not yet reviewed by founder) | “In late 2025, we initiated a Phase 2 clinical trial of ALN-6400 in patients with Hereditary Hemorrhagic Telangiectasia, or HHT, and we plan to share additional data from the Phase 1 clinical trial as well as initial results in the Phase 2 clinical trial in HHT the second half of 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 | |
| Disc Medicine, Inc. (IRON) | bitopertin Quote matched to filing (not yet reviewed by founder) | “We completed enrollment in APOLLO (n=183) in the first quarter of 2026 and expect to report topline data in the fourth quarter of 2026.” | SEC Form 10-Q | Company’s stated window: still open Days left in the window the company stated: 73 |
No program on this list has a stated period still open in Q4 2026. See the calendar.
Every program and date, with filters: the calendar. Want to hear when one of these files results? Get a free Watch.